# Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

> **NCT05467670** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alexander B Olawaiye, MD** · enrollment: 16 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** ALX148
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT05467670
- **Lead sponsor:** Alexander B Olawaiye, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-30
- **Primary completion:** 2026-04-22
- **Final completion:** 2031-01-22
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467670, "Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05467670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*